100 related articles for article (PubMed ID: 7371023)
41. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Sharma A; Straubinger NL; Straubinger RM
Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
[TBL] [Abstract][Full Text] [Related]
42. Carrot cells detoxify N-phosphonoacetyl-L-aspartate by esterification.
Cole SC; Yon RJ
Biochem J; 1988 Nov; 255(3):813-6. PubMed ID: 3214426
[TBL] [Abstract][Full Text] [Related]
43. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
Harrison SD; Giles HD; Denine EP
Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
[No Abstract] [Full Text] [Related]
44. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Grem JL; Drake JC; Allegra CJ
Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of new transition-state analogue inhibitors of aspartate transcarbamylase.
Farrington GK; Kumar A; Wedler FC
J Med Chem; 1985 Nov; 28(11):1668-73. PubMed ID: 4067992
[TBL] [Abstract][Full Text] [Related]
46. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
47. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
[TBL] [Abstract][Full Text] [Related]
48. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
50. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
51. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
[No Abstract] [Full Text] [Related]
52. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
53. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
[TBL] [Abstract][Full Text] [Related]
54. Bohr effect in Escherichia coli aspartate transcarbamylase. Linkages between substrate binding, proton binding, and conformational transitions.
Allwell NM; Hofmann GE; Zaug A; Lennick M
Biochemistry; 1979 Jul; 18(14):3008-15. PubMed ID: 37893
[No Abstract] [Full Text] [Related]
55. T-state inhibitors of E. coli aspartate transcarbamoylase that prevent the allosteric transition.
Heng S; Stieglitz KA; Eldo J; Xia J; Cardia JP; Kantrowitz ER
Biochemistry; 2006 Aug; 45(33):10062-71. PubMed ID: 16906764
[TBL] [Abstract][Full Text] [Related]
56. Submicromolar phosphinic inhibitors of Escherichia coli aspartate transcarbamoylase.
Coudray L; Kantrowitz ER; Montchamp JL
Bioorg Med Chem Lett; 2009 Feb; 19(3):900-2. PubMed ID: 19097895
[TBL] [Abstract][Full Text] [Related]
57. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Karle JM; Anderson LW; Erlichman C; Cysyk RL
Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and in vitro evaluation of aspartate transcarbamoylase inhibitors.
Coudray L; Pennebaker AF; Montchamp JL
Bioorg Med Chem; 2009 Nov; 17(22):7680-9. PubMed ID: 19828320
[TBL] [Abstract][Full Text] [Related]
59. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
Leung SW; Fung KP; Choy YM; Lee CY
Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
[TBL] [Abstract][Full Text] [Related]
60. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
Swyryd EA; Seaver SS; Stark GR
J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]